Holen Sie sich die Stockscreener-App
2.58
3.20%
0.08
Handel nachbörslich:
2.58
Schlusskurs vom Vortag:
$2.50
Offen:
$2.53
24-Stunden-Volumen:
151.93K
Relative Volume:
0.38
Marktkapitalisierung:
$146.86M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-1.4413
EPS:
-1.79
Netto-Cashflow:
$-64.50M
1W Leistung:
+0.78%
1M Leistung:
-14.00%
6M Leistung:
-63.25%
1J Leistung:
-48.19%
1-Tages-Spanne:
$2.473
$2.64
1-Wochen-Bereich:
$2.39
$2.64
52-Wochen-Spanne:
$2.305
$9.69
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
880 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
2.58 | 146.86M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
Barclays PLC Purchases 44,903 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal year - MSN
TScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent 14% pullback adds to one-year year losses, institutional owners may take drastic measures - Simply Wall St
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks - MSN
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
Jane Street Group LLC Decreases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Barclays PLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC - Defense World
State Street Corp Has $3.77 Million Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an inve - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Increased by Stifel Financial Corp - Defense World
TScan secures $30 million through warrant sale to Lynx1 By Investing.com - Investing.com Nigeria
TScan Therapeutics Refinances Existing Debt Facility with Silicon Valley Bank - Defense World
TScan Shares Jump 23% on Securities Purchase Agreement - MarketWatch
TScan Therapeutics announces ~$30M direct offering - MSN
TScan secures $30 million through warrant sale to Lynx1 - Investing.com
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - The Manila Times
TScan Therapeutics (TCRX) Secures $30M Premium-Priced Financing, Extends Cash Runway to 2027 - StockTitan
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing - Yahoo Finance
TScan Therapeutics’ (TCRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Recent Research Analysts’ Ratings Updates for TScan Therapeutics (TCRX) - Defense World
Wedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics Secures $52.5M Loan from SVB - TipRanks
TScan Therapeutics Refinances Existing Convertible Debt - GlobeNewswire
TScan Therapeutics Secures Major $52.5M Financing Deal to Extend Cash Runway Through 2026 - StockTitan
XTX Topco Ltd Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
Tscan Therapeutics Inc (TCRX-Q) QuotePress Release - The Globe and Mail
tScan Therapeutics sees $385,768 purchase by Lynx1 Capital - Investing.com
SC Pharmaceuticals Inc (SCPH-Q) QuotePress Release - The Globe and Mail
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges - Investing.com India
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges By Investing.com - Investing.com South Africa
Wedbush Cuts Earnings Estimates for TScan Therapeutics - Defense World
Equities Analysts Offer Predictions for TCRX FY2026 Earnings - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLC - Defense World
HC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics (NASDAQ: TCRX) Issues Report on Updated Phase 1 Trial Data for ALLOHA Program**On December 9, 2024, TScan Therapeutics, Inc. released a comprehensive report on the latest developments surrounding its ALLOHA ™ Phase 1 trial - Defense World
The Analyst Landscape: 5 Takes On TScan Therapeutics - Benzinga
HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from Needham & Company LLC - MarketBeat
TScan Therapeutics Announces Promising Phase 1 Trial Results - TipRanks
TScan Therapeutics to Present Updated Data from the Ongoing - GlobeNewswire
Tscan Therapeutics to Present Updated Data from the Ongoing Alloha?? Phase 1 Heme Trial During Oral Session At the 66Th American Society of Hematology Annual Meeting and Exposition - Marketscreener.com
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years - GlobeNewswire
TScan Therapeutics to Host Virtual KOL Event to Discuss - GlobeNewswire
TScan Therapeutics to Host KOL Event on Phase 1 Blood Cancer Trial Data at ASH - StockTitan
TScan issues stock in loan conversion - Investing.com
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):